Log in to search using one of your social media accounts:

 

Screening for CRC cost  effective in patients with cystic fibrosis

Source: PharmacoEconomics and Outcomes News - Category: Drugs & Pharmacology Source Type: news

Related Links:

Conclusions: The present review discusses a novel mechanism for pulmonary edema fluid reabsorption. SPMs might provide new opportunities to design "reabsorption-targeted" therapies with high degrees of precision in controlling ALI/ARDS. PMID: 29664060 [PubMed - in process]
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research
Conclusion: IT following lung and liver transplantation, with injection of islets into a transplanted organ, is feasible. It improves C-peptide secretion, decreases insulin needs, and lowers HbA1c.Horm Res Paediatr
Source: Hormone Research in Paediatrics - Category: Endocrinology Source Type: research
Hypoglycemia in cystic fibrosis (CF) patients during the oral glucose tolerance test (OGTT) has been reported; however, these patients have not been well-characterized. Few studies have examined whether hypoglycemia during the OGTT increases the risk of developing CF-related diabetes (CFRD). Objectives of this study were to describe the characteristics of CF patients with hypoglycemia during the OGTT and to determine the incidence and time to development of CFRD in those with hypoglycemia.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original Article Source Type: research
Condition:   Cystic Fibrosis Interventions:   Drug: PTI-808;   Drug: Placebo;   Drug: PTI-801;   Drug: PTI-428 Sponsor:   Proteostasis Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Lung Transplant Rejection Intervention:   Device: photopheresis Sponsors:   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico;   Italian Cystic Fibrosis Research Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause the inherited disorder cystic fibrosis (CF). Lung disease is the major cause of CF morbidity, though CFTR expression levels are substantially lower in the airway epithelium than in pancreatic duct and intestinal epithelia, which also show compromised function in CF. Recently developed small molecule therapeutics for CF are highly successful for one specific CFTR mutation and have a positive impact on others. However, the low abundance of CFTR transcripts in the airway limits the opportunity for drugs to correct the defective substrate. E...
Source: Biochemical Journal - Category: Biochemistry Authors: Tags: Research Articles Source Type: research
Pediatric Pulmonology, EarlyView.
Source: Pediatric Pulmonology - Category: Respiratory Medicine Authors: Source Type: research
Letters in Applied Microbiology, EarlyView.
Source: Letters in Applied Microbiology - Category: Microbiology Authors: Source Type: research
Conclusion Antibiotic regimens including fosfomycin appear to be clinically effective and safe. Fosfomycin should, therefore, be considered as an add-on therapy in patients who failed to respond to initial treatment and with multiple drug allergies.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research
Condition:   Cystic Fibrosis Interventions:   Device: Lung Clearance Index;   Drug: MRI with PFP Sponsors:   University of North Carolina, Chapel Hill;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cystic Fibrosis | Drugs & Pharmacology